Rubinstein-Taybi syndrome due to CREBBP mutations: genes and variants
Explore variant evidence for Rubinstein-Taybi syndrome due to CREBBP mutations across 2 analyzed proteins (CREBBP, EP300). Linked ClinVar records include 53 pathogenic or likely pathogenic variants, 175 variants of uncertain significance and 80 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Rubinstein-Taybi syndrome due to CREBBP mutations
CREBBP: CREB-binding protein
It acetylates histones and integrates signals from many transcription factors to regulate developmental and activity-dependent gene expression. Germline loss-of-function variants cause Rubinstein-Taybi syndrome, while somatic alterations occur in several cancers.
52 ClinVar pathogenic / likely pathogenic and 246 uncertain variants in CREBBP have source records linked to Rubinstein-Taybi syndrome due to CREBBP mutations. Association strength is not clinical gene validity.
EP300: Histone acetyltransferase p300
It acetylates histones and transcription factors and acts as a central coactivator for developmental and stress-responsive transcription. Germline loss-of-function variants cause Rubinstein-Taybi syndrome type 2, while acquired alterations occur in several cancers.
1 ClinVar pathogenic / likely pathogenic and 9 uncertain variants in EP300 have source records linked to Rubinstein-Taybi syndrome due to CREBBP mutations. Association strength is not clinical gene validity.
Where Rubinstein-Taybi syndrome due to CREBBP mutations variants cluster
- CREBBP CBP/p300-type HAT (positions 1323–1700): 31 of 52 ClinVar pathogenic / likely pathogenic variants, 3.9× more than its size predicts (a length-based count, not a validated hotspot).
- CREBBP Interaction with TRERF1 (positions 1460–1891): 20 of 52 ClinVar pathogenic / likely pathogenic variants, 2.2× more than its size predicts (a length-based count, not a validated hotspot).
- CREBBP Interaction with ASF1A (positions 1162–1180): 4 of 52 ClinVar pathogenic / likely pathogenic variants, 9.9× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Rubinstein-Taybi syndrome due to CREBBP mutations
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CREBBP R1378P | 1378 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP E1278K | 1278 | Pathogenic / likely pathogenic (★★) | |
| CREBBP R1378Q | 1378 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP T1426R | 1426 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP D1480G | 1480 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP R1664H | 1664 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP A1782V | 1782 | TAZ-type 2 | Pathogenic / likely pathogenic (★★) |
| CREBBP R601W | 601 | KIX | Pathogenic / likely pathogenic (★★) |
| CREBBP L608P | 608 | KIX | Pathogenic / likely pathogenic (★★) |
| CREBBP Y1175C | 1175 | Bromo | Pathogenic / likely pathogenic (★★) |
| CREBBP C1240Y | 1240 | Pathogenic / likely pathogenic (★★) | |
| CREBBP S1687F | 1687 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★★) |
| CREBBP C1720R | 1720 | ZZ-type | Pathogenic / likely pathogenic (★★) |
| CREBBP C1723W | 1723 | ZZ-type | Pathogenic / likely pathogenic (★★) |
| CREBBP L1779P | 1779 | TAZ-type 2 | Pathogenic / likely pathogenic (★★) |
| CREBBP R1786H | 1786 | TAZ-type 2 | Pathogenic / likely pathogenic (★★) |
| CREBBP D1435E | 1435 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP Y1482C | 1482 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP Y1482D | 1482 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP R1446H | 1446 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP Q1491K | 1491 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP E1278Q | 1278 | Pathogenic / likely pathogenic (★) | |
| CREBBP R1427S | 1427 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP Y1503C | 1503 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP Y1503F | 1503 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP R1664L | 1664 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP G1746V | 1746 | ZZ-type | Pathogenic / likely pathogenic (★) |
| CREBBP M1K | 1 | Pathogenic / likely pathogenic (★) | |
| CREBBP K13E | 13 | Pathogenic / likely pathogenic (★) | |
| CREBBP H365P | 365 | TAZ-type 1 | Pathogenic / likely pathogenic (★) |
| CREBBP A644P | 644 | KIX | Pathogenic / likely pathogenic (★) |
| CREBBP A1164P | 1164 | Bromo | Pathogenic / likely pathogenic (★) |
| CREBBP T1171R | 1171 | Bromo | Pathogenic / likely pathogenic (★) |
| CREBBP R1341P | 1341 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP V1361A | 1361 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP V1371D | 1371 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP P1373H | 1373 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP F1409S | 1409 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP C1421F | 1421 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP E1459G | 1459 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP S1684P | 1684 | CBP/p300-type HAT | Pathogenic / likely pathogenic (★) |
| CREBBP C1729S | 1729 | ZZ-type | Pathogenic / likely pathogenic (★) |
| CREBBP H1804Q | 1804 | TAZ-type 2 | Pathogenic / likely pathogenic (★) |
| EP300 C1250Y | 1250 | Pathogenic / likely pathogenic (★) | |
| CREBBP D1435Y | 1435 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP R1428P | 1428 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP Y1433H | 1433 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP R1347P | 1347 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP S1382F | 1382 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP R1392L | 1392 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP A1473T | 1473 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP H1487R | 1487 | CBP/p300-type HAT | Pathogenic / likely pathogenic |
| CREBBP S1179G | 1179 | Bromo | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Rubinstein-Taybi syndrome due to CREBBP mutations
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CREBBP R1378W | 1378 | CBP/p300-type HAT | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; R1378P at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.812 |
Which prediction tools work for Rubinstein-Taybi syndrome due to CREBBP mutations
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 98 out of 100
- ESM1b (LLR): 98 out of 100
- MutPred: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 88 out of 100
- SIFT: 87 out of 100
Same protein, different disease
- Menke-Hennekam syndrome also has ClinVar records linked to CREBBP variants; they fall partly in the same places as the Rubinstein-Taybi syndrome due to CREBBP mutations variants (15 pathogenic / likely pathogenic).
- Rubinstein-Taybi syndrome also has ClinVar records linked to CREBBP variants; they fall mostly in different places as the Rubinstein-Taybi syndrome due to CREBBP mutations variants (15 pathogenic / likely pathogenic).
- Rubinstein-Taybi syndrome due to EP300 haploinsufficiency also has ClinVar records linked to EP300 variants; they fall mostly in different places as the Rubinstein-Taybi syndrome due to CREBBP mutations variants (17 pathogenic / likely pathogenic).
- Menke-Hennekam syndrome also has ClinVar records linked to EP300 variants; they fall mostly in different places as the Rubinstein-Taybi syndrome due to CREBBP mutations variants (4 pathogenic / likely pathogenic).
Diseases related to Rubinstein-Taybi syndrome due to CREBBP mutations
- Menke-Hennekam syndrome, also linked to CREBBP and EP300
- Urinary bladder cancer, also linked to CREBBP and EP300
- Rubinstein-Taybi syndrome, also linked to CREBBP and EP300
- Rare genetic intellectual disability, also linked to CREBBP and EP300
- Cone-rod dystrophy, also linked to CREBBP
- Colorectal cancer, also linked to EP300
- Rubinstein-Taybi syndrome due to EP300 haploinsufficiency, also linked to EP300
- Colon carcinoma, also linked to EP300
- Head and neck squamous cell carcinoma, also linked to EP300
Frequently asked questions
Which genes have records linked to Rubinstein-Taybi syndrome due to CREBBP mutations?
This view contains 2 analyzed proteins: CREBBP, EP300. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 53 pathogenic or likely pathogenic variants, 175 variants of uncertain significance and 80 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 400 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center